CJC 1295 No DAC: Naming Convention Explained

The most common question we hear from researchers ordering CJC 1295 no DAC for the first time isn't about dosing or reconstitution—it's whether 'CJC 1295 no DAC' and 'CJC-1295 no DAC' are different compounds. They're not. The hyphen is a typographical variation that appears across supplier catalogues, research literature, and peptide forums with no functional meaning. What matters is the 'no DAC' designation—that's what separates this peptide from its modified counterpart, CJC 1295 with DAC (also called CJC 1295 DAC or Mod GRF 1-29 with DAC). The hyphen debate exists because peptide nomenclature lacks universal standardisation, so different labs, suppliers, and publications format the same compound name differently.

Our team works with research facilities that order both formats interchangeably—because they understand that CJC 1295 no DAC and CJC-1295 no DAC reference the exact same 29-amino-acid sequence. The naming confusion matters less than the DAC distinction, which fundamentally changes the peptide's half-life, dosing frequency, and research applications.

Is CJC 1295 no DAC the same as CJC-1295 no DAC?

Yes—CJC 1295 no DAC and CJC-1295 no DAC are the same peptide. Both refer to modified GRF 1-29, a growth hormone-releasing hormone (GHRH) analogue with no Drug Affinity Complex attached. The hyphen is a formatting choice that varies across suppliers and research publications but doesn't indicate a chemical difference. The critical distinction is 'no DAC' versus 'with DAC'—that determines whether the peptide has a half-life of 30 minutes (no DAC) or approximately eight days (with DAC).

Most researchers assume formatting differences signal chemical variations—but with CJC 1295 no DAC, the hyphen is purely stylistic. Some suppliers write it as CJC 1295 no DAC, others as CJC-1295 no DAC, and a few use CJC1295 no DAC without any space or hyphen. All three formats describe modified GRF 1-29 without the DAC attachment. The peptide sequence remains identical: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. This piece covers what the 'no DAC' designation actually means, why the hyphen appears inconsistently across sources, and how to verify you're ordering the correct peptide regardless of formatting.

The DAC Distinction: What 'No DAC' Actually Means

The 'no DAC' designation refers to the absence of Drug Affinity Complex—a synthetic moiety that extends peptide half-life by binding to serum albumin. CJC 1295 no DAC is unmodified modified GRF 1-29, meaning it contains the four amino acid substitutions that differentiate it from native GRF 1-29 (positions 2, 8, 15, and 27) but lacks the DAC attachment present in CJC 1295 with DAC. Without DAC, the peptide clears rapidly—half-life is approximately 30 minutes, requiring multiple daily administrations to maintain elevated growth hormone-releasing hormone (GHRH) receptor activation. With DAC, half-life extends to roughly eight days, allowing weekly dosing.

The functional difference is pharmacokinetic, not pharmacodynamic—both peptides bind the same GHRH receptor with similar affinity. CJC 1295 no DAC produces pulsatile GH release that mimics endogenous secretion patterns, while CJC 1295 with DAC creates sustained elevation that may suppress natural pulsatility over extended periods. Research protocols using CJC 1295 no DAC typically combine it with GHRP-2, GHRP-6, Ipamorelin, or Hexarelin to amplify pulsatile release—these combinations appear frequently in body composition and metabolic studies. The 'no DAC' version allows tighter control over dosing windows and avoids prolonged receptor occupancy that could theoretically downregulate GHRH receptor density.

Why the Hyphen Appears (and Disappears) Across Sources

Peptide naming conventions aren't governed by a single regulatory body—chemical nomenclature follows IUPAC rules, but commercial peptide names combine proprietary designations, research shorthand, and supplier branding. 'CJC 1295' originated from Conjuchem Biotechnologies, the company that developed the DAC-modified version in the early 2000s. When researchers began using the unmodified analogue (modified GRF 1-29), they adopted 'CJC 1295 no DAC' to distinguish it from the original compound. Some catalogues hyphenate the numeric portion (CJC-1295), some don't (CJC 1295), and others remove spacing entirely (CJC1295)—none of these variations indicate chemical differences.

The hyphen typically appears in European supplier catalogues and older research papers, while U.S.-based labs and newer publications tend to omit it. The inconsistency extends to scientific databases: PubChem lists the compound as 'Modified GRF (1-29)', Sigma-Aldrich uses 'CJC-1295 without DAC', and Real Peptides labels it 'CJC1295 Ipamorelin 5MG 5MG' when combined with Ipamorelin. All refer to the same peptide—the 29-amino-acid sequence without albumin-binding modification. Researchers ordering from multiple suppliers often see both formats on the same invoice, which fuels the perception that they're different compounds.

How to Verify You're Ordering the Correct Peptide

The most reliable verification method is requesting the amino acid sequence from your supplier—if it matches modified GRF 1-29 (Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2), the hyphen formatting is irrelevant. Certificate of Analysis (CoA) documentation should list molecular weight (3367.9 Da for the acetate salt form), purity percentage (≥98% by HPLC), and storage conditions (lyophilised powder stable at −20°C). Any reputable supplier provides batch-specific CoA data upon request—if they refuse or provide generic documentation, that's a red flag regardless of how they format the product name.

Some researchers cross-reference CAS numbers, but modified GRF 1-29 lacks a universal CAS identifier because it exists as multiple salt forms (acetate, trifluoroacetate). Instead, verify the peptide's intended half-life and dosing frequency with your supplier. If they describe a compound requiring daily or twice-daily dosing, you're ordering CJC 1295 no DAC. If they describe weekly dosing, you're ordering CJC 1295 with DAC—the naming format (hyphenated or not) doesn't change that fundamental pharmacokinetic distinction. Real Peptides synthesises every peptide through small-batch production with exact amino-acid sequencing, so whether a researcher searches our catalogue for 'CJC 1295 no DAC' or 'CJC-1295 no DAC', they receive the same verified compound.

CJC 1295 No DAC vs CJC-1295 No DAC: Comparison

This table clarifies the relationship between the two naming conventions and highlights what actually differs between peptide variants.

What If: CJC 1295 No DAC Scenarios

What If a Supplier Lists Both 'CJC 1295 No DAC' and 'CJC-1295 No DAC' as Separate Products?

Request the amino acid sequence for both listings—if they match modified GRF 1-29, they're the same compound sold under different catalogue formats. Some suppliers maintain duplicate listings for search optimisation purposes, so researchers typing either format find the product. If the sequences differ, one listing is mislabelled or refers to a different analogue entirely. Legitimate suppliers consolidate identical compounds under a single SKU—duplicate listings with different pricing suggest either poor catalogue management or intentional confusion.

What If My Certificate of Analysis Shows 'Mod GRF 1-29' Instead of 'CJC 1295 No DAC'?

That's expected—modified GRF 1-29 is the technical name for CJC 1295 no DAC, and many analytical labs use the IUPAC-derived nomenclature rather than commercial shorthand. If the molecular weight matches 3367.9 Da (acetate salt) and the sequence contains 29 amino acids with substitutions at positions 2, 8, 15, and 27, you received the correct peptide. The CoA should also confirm purity ≥98% by HPLC and list storage at −20°C for lyophilised powder.

What If I Accidentally Ordered CJC 1295 With DAC Instead of No DAC?

The practical consequence is dosing frequency—CJC 1295 with DAC requires weekly administration rather than daily or twice-daily. If your research protocol depends on pulsatile GH release (the pattern CJC 1295 no DAC provides), the sustained elevation from the DAC version won't replicate that pharmacokinetic profile. Verify your order by checking the product description for half-life or dosing instructions—'weekly dosing' indicates you received the DAC version, 'daily dosing' confirms the no DAC version.

The Blunt Truth About Peptide Naming Conventions

Here's the honest answer: peptide suppliers don't use hyphens consistently because there's no regulatory body enforcing formatting standards. CJC 1295 no DAC, CJC-1295 no DAC, and CJC1295 no DAC all describe modified GRF 1-29 without Drug Affinity Complex—the hyphen exists because different catalogues adopted different typographic styles, not because it signals a chemical distinction. Researchers waste time comparing 'hyphenated vs non-hyphenated' versions when the actual verification step is requesting the amino acid sequence or Certificate of Analysis. The confusion is profitable for low-quality suppliers who create artificial product differentiation through formatting tricks, listing the same compound multiple times under slightly different names to appear like they offer more variety.

The real dividing line isn't the hyphen—it's the DAC designation. CJC 1295 no DAC has a 30-minute half-life and produces pulsatile GH release; CJC 1295 with DAC has an eight-day half-life and creates sustained elevation. That difference matters for research design. Whether you write it with or without a hyphen doesn't. Our experience working with hundreds of research labs is that the best verification method is asking three questions: What's the amino acid sequence? What's the molecular weight? What's the recommended dosing frequency? If those answers align with modified GRF 1-29 specifications, the hyphen is irrelevant.

The peptide research industry runs on precision—exact sequences, verified purity, controlled storage. Formatting inconsistencies in product names don't reflect the quality of the underlying compound, but they do test whether a researcher knows how to verify what they're ordering. The hyphen debate is a filtering mechanism: labs that understand peptide chemistry ignore it and check the CoA; labs that don't understand peptide chemistry fixate on formatting and miss the actual quality signals. Real Peptides guarantees purity and consistency through small-batch synthesis with exact amino-acid sequencing—whether you search our catalogue for CJC 1295 no DAC or CJC-1295 no DAC, you receive the same verified compound backed by batch-specific analytical documentation.

Understand the distinction that matters—'no DAC' versus 'with DAC'—and ignore the hyphen. Verify through sequencing, not through naming format. That's the standard every serious research facility follows, and it's the only way to ensure you're working with the peptide your protocol requires.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

1. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
2. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
3. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
4. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
5. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
6. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
7. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286